These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25800124)

  • 1. Recent advances in endocrine metabolic immune disorders drug targeting: an editorial overview.
    Magrone T; Jirillo E
    Endocr Metab Immune Disord Drug Targets; 2015; 15(1):1-8. PubMed ID: 25800124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correction of immunometabolic disorders in chronic bacterial prostatitis].
    Shatokhin MN; Teodorovich OV; Konoplia AI; Gavriliuk VP; Mavrin MIu; Krasnov AV
    Urologiia; 2011; (5):39-42. PubMed ID: 22279785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the exploration of therapeutic targets for the treatment of endocrine, metabolic and immune disorders.
    Chen X; Zheng CJ; Han LY; Xie B; Chen YZ
    Endocr Metab Immune Disord Drug Targets; 2007 Sep; 7(3):225-31. PubMed ID: 17897049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch: a unique therapeutic target for immunomodulation.
    McKenzie GJ; Khan M; Briend E; Stallwood Y; Champion BR
    Expert Opin Ther Targets; 2005 Apr; 9(2):395-410. PubMed ID: 15934923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin as clinical target.
    Cai C; Shi FD; Matarese G; La Cava A
    Recent Pat Inflamm Allergy Drug Discov; 2009 Nov; 3(3):160-6. PubMed ID: 19594439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
    Lopalco G; Rigante D; Giannini M; Galeazzi M; Lapadula G; Iannone F; Cantarini L
    Clin Exp Rheumatol; 2016; 34(3):531-8. PubMed ID: 26940286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-Targeted Therapeutics for Metabolic Disease.
    Peterson KR; Cottam MA; Kennedy AJ; Hasty AH
    Trends Pharmacol Sci; 2018 Jun; 39(6):536-546. PubMed ID: 29628274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting bile-acid signalling for metabolic diseases.
    Thomas C; Pellicciari R; Pruzanski M; Auwerx J; Schoonjans K
    Nat Rev Drug Discov; 2008 Aug; 7(8):678-93. PubMed ID: 18670431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks?
    Korkina L; Trakhtman P; De Luca C; Leoni L; Raskovic D; Pastore S
    Drugs Today (Barc); 2010 Feb; 46(2):119-36. PubMed ID: 20393640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 11. Microbial contributions to chronic inflammation and metabolic disease.
    Shanahan F; Sheehan D
    Curr Opin Clin Nutr Metab Care; 2016 Jul; 19(4):257-62. PubMed ID: 27097361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades?
    Abdollahi E; Momtazi AA; Johnston TP; Sahebkar A
    J Cell Physiol; 2018 Feb; 233(2):830-848. PubMed ID: 28059453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-Target Drugs Against Metabolic Disorders.
    Scotti L; Scotti MT
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):389-390. PubMed ID: 31274061
    [No Abstract]   [Full Text] [Related]  

  • 15. Multi-Target Drugs Against Metabolic Disorders.
    Scotti L; Monteiro AFM; de Oliveira Viana J; Mendonça Junior FJB; Ishiki HM; Tchouboun EN; Santos R; Scotti MT
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):402-418. PubMed ID: 30556507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bacterial lipopolysaccharides as immune modulator in vaccine and drug development.
    Arenas J
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):221-35. PubMed ID: 22385116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial overview: Endocrine and metabolic diseases: Busting BMI: new strategies for the treatment of obesity and metabolic disease.
    Bewick GA
    Curr Opin Pharmacol; 2017 Dec; 37():ix-xii. PubMed ID: 29224800
    [No Abstract]   [Full Text] [Related]  

  • 18. Questions about coenzyme Q-10.
    Daiell R
    Altern Ther Health Med; 2002; 8(6):18; author reply 18. PubMed ID: 12440833
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting the CB2 receptor for immune modulation.
    Lunn CA; Reich EP; Bober L
    Expert Opin Ther Targets; 2006 Oct; 10(5):653-63. PubMed ID: 16981823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut microbiota: A treasure for human health.
    Li D; Wang P; Wang P; Hu X; Chen F
    Biotechnol Adv; 2016 Nov; 34(7):1210-1224. PubMed ID: 27592384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.